首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Thiosemicarbazone-based lead optimization to discover high-efficiency and low-toxicity anti-gastric cancer agents
【24h】

Thiosemicarbazone-based lead optimization to discover high-efficiency and low-toxicity anti-gastric cancer agents

机译:基于硫代虫毒的铅优化,以发现高效率和低毒性的抗胃癌药剂

获取原文
获取原文并翻译 | 示例
           

摘要

In this paper, a series of thiosemicarbazone derivatives containing different aromatic heterocyclic groups were synthesized and the tridentate donor system of the lead compound was optimized. Most of the target compounds showed improved antiproliferative activity against MGC803 cells. SAR studies revealed that compound 5d displayed significant advantages in inhibition effect with an IC50 value of 0.031 mu M, and better selectivity between cancer and normal cells than 3-AP and DpC (about 15- and 5-fold improved respectively). Besides, compound 5d showed selective antiproliferative activity in not only other cancer cells but also different gastric cancer cell lines. In-depth mechanism studies showed that compound 5d could induce mitochondria-related apoptosis which might be related to the elevation of intracellular ROS level, and cause cell cycle arrest at S phase. Moreover, 5d could evidently suppress the cell migration and invasion by blocking the EMT (epithelial-mesenchymal transition) process. Consequently, our studies provided a lead optimization strategy of thiosemicarbazone derivatives which would contribute to discover high-efficiency and low-toxicity agents for the treatment of gastric cancer. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:本文合成了含有不同芳族杂环基的一系列硫代喹甲衍生物,并优化了铅化合物的三叉子供体体系。大多数目标化合物显示出对MGC803细胞的改善的抗增殖活性。 SAR研究表明,化合物5D在抑制作用抑制作用的显着优势,IC50值为0.031μm,癌症和正常细胞之间的选择性优于3-AP和DPC(分别为约15倍)。此外,化合物5D不仅在其他癌细胞中显示出选择性抗增殖活性,而且表现出不同的胃癌细胞系。深入的机制研究表明,化合物5D可以诱导与细胞内ROS水平的升高有关的线粒体相关的凋亡,并在S期引起细胞周期停滞。此外,通过阻断EMT(上皮 - 间充质转换)过程,5D可以显然抑制细胞迁移和侵袭。因此,我们的研究提供了硫代蓟虫毒素衍生物的铅优化策略,这些衍生物将有助于发现用于治疗胃癌的高效率和低毒性药剂。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

  • 来源
  • 作者单位

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

    Zhengzhou Univ Collaborat Innovat Ctr New Drug Res &

    Safety Eval Sch Pharmaceut Sci Key Lab Adv;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

    Thiosemicarbazone; Lead optimization; Gastric cancer; Migration;

    机译:硫代虫吩;铅优化;胃癌;迁移;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号